Top

Published in:

01-09-2016 | Review Article

Venous thromboembolism following hematopoietic stem cell transplantation—a systematic review and meta-analysis

Authors: Mohammad Faizan Zahid, M. Hassan Murad, Mark R. Litzow, William J. Hogan, Mrinal S. Patnaik, Alok Khorana, Alex C. Spyropoulos, Shahrukh K. Hashmi

Published in: Annals of Hematology | Issue 9/2016

Abstract

Venous thromboembolism (VTE) is a common complication of hematopoietic stem cell transplantation (HSCT). Graft-versus-host disease (GVHD) is another complication of HSCT that may modify the risk of VTE. Our objective was to explore the incidence of VTE (deep venous thrombosis and pulmonary embolism) following HSCT and to evaluate its association with GVHD. A comprehensive search of Medline In-Process & Other Non-Indexed Citations, MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Scopus was conducted to search for both retrospective and prospective HSCT studies which had reported VTE. Random-effects meta-analysis was used to pool incidence rates. We included 17 studies reporting on allogeneic- and 10 on autologous-HSCT; enrolling 6693 patients; of which 5 were randomized. The overall incidence of VTE after HSCT was 5 % (4–7 %). Incidence in allogeneic-HSCT was 4 % (2–6 %) and in autologous-HSCT was 4 % (1–15 %). Eleven and nine studies reported data on acute and chronic GVHD, respectively. The incidence of VTE in chronic GVHD was 35 % (20–54 %), whereas in acute GVHD it was 47 % (32–62 %). Based on the results of this meta-analysis, VTE is a fairly common complication after HSCT, emphasizing the importance of assimilating guidelines for both treatment and prophylaxis in this patient population.

Available only for authorised users

Labrador J, Lopez-Anglada L, Perez-Lopez E, Lozano FS, Lopez-Corral L, Sanchez-Guijo FM et al (2013) Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients. Haematologica 98(3):437–443CrossRefPubMedPubMedCentral

Gerber DE, Segal JB, Levy MY, Kane J, Jones RJ, Streiff MB (2008) The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. Blood 112(3):504–510CrossRefPubMed

Gonsalves A, Carrier M, Wells PS, McDiarmid SA, Huebsch LB, Allan DS (2008) Incidence of symptomatic venous thromboembolism following hematopoietic stem cell transplantation. J Thromb Haemost 6(9):1468–1473CrossRefPubMed

Pihusch R, Salat C, Schmidt E, Göhring P, Pihusch M, Hiller E et al (2002) Hemostatic complications in bone marrow transplantation: a retrospective analysis of 447 patients. Transplantation 74(9):1303–1309CrossRefPubMed

Tsakiris DA, Tichelli A (2009) Thrombotic complications after haematopoietic stem cell transplantation: early and late effects. Best Pract Res Clin Haematol 22(1):137–145CrossRefPubMed

Carreras E (ed) (2012) Early complications after HSCT. The EBMT handbook on haematopoietic stem cell transplantation Forum Service, Genova

Copelan EA (2006) Hematopoietic stem-cell transplantation. N Engl J Med 354(17):1813–1826CrossRefPubMed

Helmy A (2006) Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome. Aliment Pharmacol Ther 23(1):11–25CrossRefPubMed

Cutler C, Henry NL, Magee C, Li S, Kim HT, Alyea E et al (2005) Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11(7):551–557CrossRefPubMed

10.

Kojouri K, George JN (2007) Thrombotic microangiopathy following allogeneic hematopoietic stem cell transplantation. Curr Opin Oncol 19(2):148–154CrossRefPubMed

11.

Pihusch M (ed) (2004) Bleeding complications after hematopoietic stem cell transplantation. Semin Hematol 41(Suppl 1):93–100

12.

Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354(10):1021–1030CrossRefPubMed

13.

Russell JA, Duan Q, Chaudhry MA, Savoie ML, Balogh A, Turner AR et al (2008) Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease. Biol Blood Marrow Transplant 14(8):888–895CrossRefPubMed

14.

Tichelli A, Gratwohl A (2008) Vascular endothelium as ‘novel’ target of graft-versus-host disease. Best Pract Res Clin Haematol 21(2):139–148CrossRefPubMed

15.

Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264–269CrossRefPubMed

16.

Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928CrossRefPubMedPubMedCentral

17.

Johnston L, Florek M, Armstrong R, McCune JS, Arai S, Brown J et al (2012) Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Bone Marrow Transplant 47(4):581–588CrossRefPubMed

18.

Wadhwa PD, Fu P, Koc ON, Cooper BW, Fox RM, Creger RJ et al (2005) High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality. Biol Blood Marrow Transplant 11(1):13–22CrossRefPubMed

19.

Lonial S, Kaufman J, Tighiouart M, Nooka A, Langston AA, Heffner LT et al (2010) A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose-and schedule-finding study. Clin Cancer Res 16(20):5079–5086CrossRefPubMed

20.

Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E et al (2011) Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 12(13):1195–1203CrossRefPubMedPubMedCentral

21.

Wells GA, Shea B, O’connell D, Peterson JEA, Welch V, Losos M et al (2000) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses

22.

Chiusolo P, Sica S, De Stefano V, Casorelli I, Laurenti L, Leone G (2000) Incidence of Factor V Leiden and prothrombin G20210A in patients submitted to stem cell transplantation. Haematologica 85(6):670–671PubMed

23.

Maris MB, Sandmaier BM, Storer BE, Maloney DG, Shizuru JA, Agura E et al (2006) Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Transplant 12(4):454–465CrossRefPubMed

24.

de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C et al (2004) Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104(3):865–872CrossRefPubMed

25.

Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS et al (2008) Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111(12):5530–5536CrossRefPubMedPubMedCentral

26.

Uderzo C, Marraro G, Riva A, Bonanomi E, Vaj PL, Marchi PF et al (1993) Pulmonary thromboembolism in leukaemic children undergoing bone marrow transplantation. Bone Marrow Transplant 11(3):201–203PubMed

27.

Chevret S, Chagnon K, Petropoulou A, Robin M, Desseaux K, de Latour RP et al (2011) Prospective evaluation of the incidence, risk factors and clinical outcome of late onset non infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 183:A4667

28.

Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ (2002) Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 20(8):2017–2024CrossRefPubMed

29.

Woodard JP, Gulbahce E, Shreve M, Steiner M, Peters C, Hite S et al (2000) Pulmonary cytolytic thrombi: a newly recognized complication of stem cell transplantation. Bone Marrow Transplant 25(3):293–300CrossRefPubMed

30.

Smith AR, Gulbahce E, Burke MJ, Cao Q, MacMillan ML, Tolar J et al (2011) Lower leukemia relapse in pediatric patients with pulmonary cytolytic thrombi following allogeneic transplant. Bone Marrow Transplant 46(3):368–371CrossRefPubMed

31.

Pihusch M, Lohse P, Reitberger J, Hiller E, Andreesen R, Kolb H-J et al (2004) Impact of thrombophilic gene mutations and graft-versus-host disease on thromboembolic complications after allogeneic hematopoietic stem-cell transplantation. Transplantation 78(6):911–918CrossRefPubMed

32.

Richters A, Van Vliet M, Peer PGM, Verweij PE, Laros-van Gorkom BAP, Blijlevens NMA et al (2014) Incidence of and risk factors for persistent gram-positive bacteraemia and catheter-related thrombosis in haematopoietic stem cell transplantation. Bone Marrow Transplant 49(2):264–269CrossRefPubMed

33.

Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC (2013) Epidemiology of cancer-associated venous thrombosis. Blood 122(10):1712–1723CrossRefPubMed

34.

Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902–4907CrossRefPubMedPubMedCentral

35.

Fujimori Y, Takatsuka H, Takemoto Y, Hara H, Okamura H, Nakanishi K et al (2000) Elevated interleukin (IL)-18 levels during acute graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 109(3):652–657CrossRefPubMed

36.

Jadus MR, Wepsic HT (1992) The role of cytokines in graft-versus-host reactions and disease. Bone Marrow Transplant 10(1):1–14PubMed

37.

Behar E, Chao NJ, Hiraki DD, Krishnaswamy S, Brown BW, Zehnder JL et al (1996) Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease. N Engl J Med 334(5):286–291CrossRefPubMed

38.

Maruya E, Saji H, Seki S, Fujii Y, Kato K, Kai S et al (1998) Evidence that CD31, CD49b, and CD62L are immunodominant minor histocompatibility antigens in HLA identical sibling bone marrow transplants. Blood 92(6):2169–2176PubMed

39.

Shulman HM, Cardona DM, Greenson JK, Hingorani S, Horn T, Huber E et al (2015) NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. The 2014 Pathology Working Group Report. Biol Blood Marrow Transplant 21(4):589–603CrossRefPubMedPubMedCentral

40.

Biedermann BC, Sahner S, Gregor M, Tsakiris DA, Jeanneret C, Pober JS et al (2002) Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 359(9323):2078–2083CrossRefPubMed

41.

Palomo M, Diaz-Ricart M, Carbo C, Rovira M, Fernandez-Aviles F, Martine C et al (2010) Endothelial dysfunction after hematopoietic stem cell transplantation: role of the conditioning regimen and the type of transplantation. Biol Blood Marrow Transplant 16(7):985–993CrossRefPubMed

42.

Schmid PM, Bouazzaoui A, Doser K, Schmid K, Hoffmann P, Schroeder JA et al (2014) Endothelial dysfunction and altered mechanical and structural properties of resistance arteries in a murine model of graft-versus-host disease. Biol Blood Marrow Transplant 20(10):1493–1500CrossRefPubMed

43.

Pophali PA, Klotz JK, Ito S, Jain NA, Koklanaris E, Le RQ et al (2014) Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events. Exp Hematol 42(2):83–89CrossRefPubMed

44.

Rovó A, Tichelli A (ed) (2012) Cardiovascular complications in long-term survivors after allogeneic hematopoietic stem cell transplantation. Seminars in hematology. Elsevier

45.

Tichelli A, Bucher C, Rovó A, Stussi G, Stern M, Paulussen M et al (2007) Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood 110(9):3463–3471CrossRefPubMed

46.

Nürnberger W, Willers R, Burdach S, Göbel U (1997) Risk factors for capillary leakage syndrome after bone marrow transplantation. Ann Hematol 74(5):221–224CrossRefPubMed

47.

Spitzer TR (2001) Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 27(9):893–898CrossRefPubMed

48.

Yabe H, Yabe M, Koike T, Shimizu T, Morimoto T, Kato S (2010) Rapid improvement of life-threatening capillary leak syndrome after stem cell transplantation by bevacizumab. Blood 115(13):2723–2724CrossRefPubMed

Title: Venous thromboembolism following hematopoietic stem cell transplantation—a systematic review and meta-analysis
Authors: Mohammad Faizan Zahid
M. Hassan Murad
Mark R. Litzow
William J. Hogan
Mrinal S. Patnaik
Alok Khorana
Alex C. Spyropoulos
Shahrukh K. Hashmi
Publication date: 01-09-2016
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 9/2016
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-016-2673-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Venous thromboembolism following hematopoietic stem cell transplantation—a systematic review and meta-analysis

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2016

Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis

Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis

The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase

Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan

The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis

Hereditary xerocytosis, a misleading anemia

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page